What the pulmonary specialist should know about the new inhalation therapies

B.L. Laube, H.M. Janssens, F.H.C. de Jongh, et al.

Source: Guideline 2011
Number: 2011

PDF journal article, handout or slides

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B.L. Laube, H.M. Janssens, F.H.C. de Jongh, et al.. What the pulmonary specialist should know about the new inhalation therapies. Guideline 2011

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

Beatrice Konamah - 06.07.2013 00:09
excellent material
You must Login to comment this presentation.

Related content which might interest you:
What the pulmonary specialist should know about the new inhalation therapies
Source: Eur Respir J 2011; 37: 1308-1417
Year: 2011

What does the future hold for pulmonary rehabilitation?
Source: Eur Respir Monogr 2021; 93: 311-325
Year: 2021

Pathophysiology of pulmonary hypertension: what the interested clinician needs to know
Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Year: 2020

Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation?
Source: International Congress 2019 – Hot topics in pulmonary rehabilitation
Year: 2019

Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready?
Source: Eur Respir J 2014; 44: 1404-1407
Year: 2014

Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow
Source: Eur Respir J, 58 (2) 2102008; 10.1183/13993003.02008-2021
Year: 2021

Are we ready for home treatment of acute pulmonary embolism?
Source: International Congress 2014 – Current controversies in the management of acute pulmonary embolism
Year: 2014

What happens after pulmonary rehabilitation?
Source: Eur Respir Monogr 2021; 93: 218-230
Year: 2021

Is there room for further innovation in inhaled therapy for airways disease?
Source: Breathe, 14 (3) 216; 10.1183/20734735.020318
Year: 2018

Predicting physician decision to prescribe systemic corticosteroids following an exacerbation of airways disease
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019

An evidence-based and step-wise approach to treat pulmonary sarcoidosis with old and new drugs
Source: International Congress 2019 – State of the art session: Interstitial lung diseases
Year: 2019

COPD guides and inhaled corticosteroids. Is there an adequate use in primary care?
Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care
Year: 2016

“I don’t think there’s a simple way of doing it:” the use of an electronic alert to identify excessive prescribing of short-acting beta2-agonists for people with asthma – a qualitative study with asthma experts and primary care staff
Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care
Year: 2020

Physicians’ and patients’ expectations of therapies for pulmonary arterial hypertension: where do they meet?
Source: Eur Respir Rev 2014; 23: 458-468
Year: 2014

Expanding the scope of pulmonary rehabilitation
Source: Annual Congress 2005 - The ERS/ATS statements on pulmonary rehabilitation
Year: 2005

The effectiveness of pulmonary rehabilitation including occupational therapy in patients with chronic pulmonary emphysema
Source: Eur Respir J 2002; 20: Suppl. 38, 376s
Year: 2002

Whither pulmonary rehabilitation? Will alternative modes help or hurt?
Source: Eur Respir J, 52 (4) 1801678; 10.1183/13993003.01678-2018
Year: 2018

Repurposing benzbromarone for pulmonary arterial hypertension: can channelling the past deliver the therapy of the future?
Source: Eur Respir J, 53 (6) 1900583; 10.1183/13993003.00583-2019
Year: 2019